Author Archives: Raymond W. Nims

Cell Banking in the Spotlight: Advising Biologics Developers About Cell Bank Preparation and Characterization

by , and

Living cells are at the heart of biotechnology, and cell lines for production and testing of biopharmaceuticals are highly valuable assets. The process of banking cells generally moves from development of a research cell bank (RCB) based on a clone of interest to establishment of a master cell bank (MCB), from which working cell banks (WCBs) can be produced. Especially for biotechnology startups, preparation of an MCB can involve a significant jump from work performed in standard laboratory conditions to…

June 7, 2021

Contractor Responsibilities in Outsourced Pharmaceutical Quality Control Testing

by and

    Pharmaceutical companies of all sizes outsource at least some quality control (QC) testing to contract analytical testing laboratories. Virtual and smaller companies may not have the staff to conduct such testing, whereas mid- to large-size companies may outsource testing that they do not wish to perform in-house. In the relationship between a pharmaceutical company and its outsourcing partner, each partner has clearly delineated responsibilities, both business and compliance related. In May 2010, we discussed a contractee’s (contract giver’s)…

June 1, 2010

Contractee Responsibilities in Outsourced Pharmaceutical Quality Control Testing

by and

    Certain types of quality control (QC) testing are often outsourced by pharmaceutical companies, regardless of an organization’s size — typically because the company is either incapable of performing the assays in-house or does not wish to bring them into its facility. The decision to outsource may be based on the complexity of techniques involved special skills required for conducting the assays a need for biohazardous reagents such as radioisotopes limited testing frequency for the assays or (in biologics…

May 1, 2010